Plate Nº 78 · recorded October 30, 2026
Health & Medicine ResearchReported finding
Implant Converts Blood Sugar Into Harmless Byproduct in Diabetes Breakthrough
An ETH Zurich team built a wireless implant that turns blood glucose into a harmless byproduct, steadying blood sugar and cutting weight 10% in mice.
By Priya Raman3 min read698 words
In brief
- Mice with the implant lost 10% of body weight over six weeks with more stable blood sugar.
- The study, published Oct. 22 in Science, comes from ETH Zurich's Fussenegger lab.
- About 790 million people have type 2 diabetes; over 1 billion have obesity.
- The device converted glucose to gluconate in a 5-liter sugary solution, matching human blood volume.
- Human trials have not yet begun; larger-animal studies are next.
Lab mice fitted with a new implant lost an average of 10% of their body weight and maintained far more stable blood sugar than untreated animals, according to a study published Oct. 22 in the journal Science. The inch-long device, developed by researchers at ETH Zurich, removes excess sugar directly from the bloodstream using a chemical reaction driven by tiny amounts of electricity.
The results come from six weeks of testing in mice with both diabetes and obesity. The implant prevented sudden insulin spikes and promoted fat loss, and it did so without drugs. Study co-author Martin Fussenegger, a professor of biotechnology and bioengineering at ETH Zurich, told Live Science the approach "could offer a completely new way to treat diabetes and obesity."
Why does the target matter?
About 790 million people worldwide live with type 2 diabetes, and more than 1 billion have obesity. Roughly 90% of people with type 2 diabetes are also overweight or living with obesity. In many of these patients, cells stop responding well to insulin (the hormone that lets cells absorb sugar from the blood), a condition called insulin resistance. The body initially compensates by making more insulin, but it eventually falls behind, paving the way for prediabetes and type 2 diabetes.
Meanwhile, the liver converts surplus blood glucose into fat stores, compounding weight gain. Current treatments rely on lifestyle changes or long-term medications: metformin, which lowers blood sugar, and GLP-1 drugs, which curb appetite. Fussenegger and his colleagues asked a different question: what if they could target the glucose itself?
How does the implant work?
The device is a small reactor that converts glucose into gluconate, a harmless byproduct, through a controlled reaction at an electrode coated with gold and platinum nanoparticles (engineered particles mere billionths of a meter across) embedded in graphite felt. The reaction runs only when the implant receives sufficient electricity, so glucose removal can simply be switched on and off by adjusting the power supply.
The system is wireless. An ordinary smartphone emits low-level radio frequency energy; the implant's electronics convert that into a stable direct current to activate the reaction. Paired with a continuous glucose monitor (a sensor that tracks blood sugar in real time), the device detects high readings and feeds the data back to the phone, which then dials the power up or down.
"In principle, this enables the device to remove more glucose when [blood sugar] levels are elevated and reduce its activity when glucose returns towards the desired range," Fussenegger said. "The objective is to create an autonomous system that continuously adapts to the patient's metabolic needs."
What did the experiments show?
Over six weeks, mice with the implant held steadier blood sugar levels than untreated mice. Because their glucose stayed consistently within the normal range, their metabolism shifted toward burning fat. The on-off regulation also kept sugar from dropping below safe limits.
To probe whether the chemistry could scale to a human-sized system, the team placed the device in a beaker holding about 1.3 gallons (5 liters) of sugary solution — a volume comparable to a person's total blood. It still controlled sugar levels effectively in that larger setting.
What are the limitations?
The findings remain a proof of concept. The tests involved mice and a laboratory beaker, not people.
"One important challenge is demonstrating that the device can convert sufficient quantities of glucose in a human while maintaining long-term safety and catalytic efficiency," Fussenegger said. The reaction must work at a far larger scale to treat a patient. Studies in larger animals and, eventually, humans are the team's next priority.
The researcher also stressed the device's intended role. "Our device is not intended to replace healthy nutrition, physical activity, or preventative medicine," he said. "Obesity and type 2 diabetes are complex conditions involving much more than elevated glucose levels. We see it as a potentially powerful addition to the therapeutic toolbox, one that could eventually be combined with established treatments and lifestyle interventions."
For now, an implant that quietly siphons sugar from the blood remains a laboratory promise — one that has cleared its first, mouse-sized hurdle.
via doi.org (Original)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
280 articles
Nearby plates
- Electric Implant Cuts Blood Sugar Without Drugs — In Mice, So Far
- Early Trial: Some Type 1 Diabetes Patients Off Insulin
- Retatrutide Helped People Lose 30% of Body Weight
- Diet and Exercise Reverse Early-Onset Type 2 Diabetes in Half of Cases
- All 12 Trial Participants Off Insulin After Tegoprubart Treatment